Original Article Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms

Marcus C. Ravnan, Mazen S. Matalka, Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma Clinical Therapeutics. ,vol. 34, pp. 1474- 1486 ,(2012) , 10.1016/J.CLINTHERA.2012.06.009

Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N. Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets, Elizabeth A. Burton, Bernice Wong, Garson Tsang, Brian L. West, Ben Powell, Rafe Shellooe, Adhirai Marimuthu, Hoa Nguyen, Kam Y. J. Zhang, Dean R. Artis, Joseph Schlessinger, Fei Su, Brian Higgins, Raman Iyer, Kurt D’Andrea, Astrid Koehler, Michael Stumm, Paul S. Lin, Richard J. Lee, Joseph Grippo, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Paul B. Chapman, Keith T. Flaherty, Xiaowei Xu, Katherine L. Nathanson, Keith Nolop, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma Nature. ,vol. 467, pp. 596- 599 ,(2010) , 10.1038/NATURE09454

Fred M. Kaplan, Curtis H. Kugel, Neda Dadpey, Yongping Shao, Ethan V. Abel, Andrew E. Aplin, SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. Journal of Biological Chemistry. ,vol. 287, pp. 41797- 41807 ,(2012) , 10.1074/JBC.M112.390906

Samuel Aparicio, Carlos Caldas, None, The Implications of Clonal Genome Evolution for Cancer Medicine The New England Journal of Medicine. ,vol. 368, pp. 842- 851 ,(2013) , 10.1056/NEJMRA1204892

R.J. Sullivan, K.T. Flaherty, Major therapeutic developments and current challenges in advanced melanoma. British Journal of Dermatology. ,vol. 170, pp. 36- 44 ,(2014) , 10.1111/BJD.12698

Jose M Pimiento, Eileen M Larkin, Keiran SM Smalley, Ginger L Wiersma, Noel R Monks, Inna V Fedorenko, Chelsea A Peterson, Brian J Nickoloff, Melanoma genotypes and phenotypes get personal Laboratory Investigation. ,vol. 93, pp. 858- 867 ,(2013) , 10.1038/LABINVEST.2013.84

Stanley P. L. Leong, Martin C. Mihm, George F. Murphy, Dave S. B. Hoon, Mohammed Kashani-Sabet, Sanjiv S. Agarwala, Jonathan S. Zager, Axel Hauschild, Vernon K. Sondak, Valerie Guild, John M. Kirkwood, Progression of cutaneous melanoma: implications for treatment Clinical & Experimental Metastasis. ,vol. 29, pp. 775- 796 ,(2012) , 10.1007/S10585-012-9521-1

Ramin Nazarian, Hubing Shi, Qi Wang, Xiangju Kong, Richard C. Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar, Thinle Chodon, Stanley F. Nelson, Grant McArthur, Jeffrey A. Sosman, Antoni Ribas, Roger S. Lo, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature. ,vol. 468, pp. 973- 977 ,(2010) , 10.1038/NATURE09626

Poulikos I. Poulikakos, Yogindra Persaud, Manickam Janakiraman, Xiangju Kong, Charles Ng, Gatien Moriceau, Hubing Shi, Mohammad Atefi, Bjoern Titz, May Tal Gabay, Maayan Salton, Kimberly B. Dahlman, Madhavi Tadi, Jennifer A. Wargo, Keith T. Flaherty, Mark C. Kelley, Tom Misteli, Paul B. Chapman, Jeffrey A. Sosman, Thomas G. Graeber, Antoni Ribas, Roger S. Lo, Neal Rosen, David B. Solit, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature. ,vol. 480, pp. 387- 390 ,(2011) , 10.1038/NATURE10662

Hubing Shi, Gatien Moriceau, Xiangju Kong, Mi-Kyung Lee, Hane Lee, Richard C. Koya, Charles Ng, Thinle Chodon, Richard A. Scolyer, Kimberly B. Dahlman, Jeffrey A. Sosman, Richard F. Kefford, Georgina V. Long, Stanley F. Nelson, Antoni Ribas, Roger S. Lo, Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications. ,vol. 3, pp. 724- 724 ,(2012) , 10.1038/NCOMMS1727